^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

sequential different B cell antigen-targeted CAR T-cell therapy

i
Other names: sequential different B cell antigen-targeted CAR T-cell therapy, sequentialB antigen chimeric antigen receptor T cells
Associations
Trials
Company:
Beijing Boren Hospital
Drug class:
CD19-targeted CAR-T immunotherapy, CD20-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
Related drugs:
Associations
Trials
3years
Efficacy and Safety of Sequential Different B Cell Antigen-Targeted CAR T-Cell Therapy for Pediatric Refractory/Relapsed Burkitt Lymphoma with Secondary Central Nervous System Involvement (ASH 2021)
The patients who achieved an ongoing complete response (CR) did not receive further therapy; for patients who retained a partial response (PR) or no response (NR) until m CD19 CAR T cells became undetectable in PB by flow cytometry (FCM), the second hCD22 CAR T-cell infusion was initiated so that it did not prematurely interfere with the antitumor effect of m CD19 CAR T cells, and could prevent disease progression in the setting of continuous m CD19 CAR T-cell contraction; and for patients who had progressive disease (PD) or relapsed disease (RD) after responding to m CD19 CAR T cells, considering that the tumor had already produced immune escape from m CD19 CAR T cells, regardless of whether there were m CD19 CAR T cells detectable in PB by FCM, the second hCD22 CAR T-cell infusion was immediately initiated. CONCLUSION S equential CAR T-cell therapy may result in a durable response and is safe in pediatric r/r Burkitt lymphoma. Patients with secondary CNS involvement may benefit from s equential CAR T-cell therapy.
Clinical • CAR T-Cell Therapy
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
LymphoCide Y-90 (epratuzumab Y-90) • sequential different B cell antigen-targeted CAR T-cell therapy